Roche/Genentech: Herceptin poised for an expanded role

Scientists have found that HER-2 is a key contributor to the development of pre-invasive breast cancer. Roche/Genentech's Herceptin, currently used to treat advanced breast cancer, can target HER-2. However, the detection of elevated HER-2 is not routine among most physicians. Despite this, Herceptin is well positioned to build its usage in early-stage and pre-cancerous populations.

Published By Datamonitor

Roche/deCODE: a renewed partnership

Published By Datamonitor

Roche/Chugai: pharmaceuticals consolidation reaches Japan

The Swiss pharmaceutical giant Roche arose from slumber earlier this week, announcing its merger with Chugai. Although the move will benefit both Roche and Chugai, and marks an important milestone in the globalization of the industry in Japan, Roche still needs to do more to accelerate its growth and catch up with its peers.

Published By Datamonitor

Roche/Chugai: gather more positive data for Actemra

The latest Phase III study results for Actemra confirm previous findings that the drug is a safe and effective biologic therapy for rheumatoid arthritis sufferers. In particular, Actemra will be a therapy for niche rheumatoid arthritis patients who do not adequately respond to anti-TNF or traditional disease-modifying drugs, further strengthening the immunology franchise of Roche and Chugai.

Published By Datamonitor

Roche reinforces its HIV portfolio

Recently presented data has highlighted the efficacy of Roche and Trimeris' Fuzeon plus new antiretrovirals in treatment-experienced HIV patients. The data forms part of an ongoing program of studies into the use of Fuzeon with several pipeline drugs, including the novel CCR5 inhibitors, and underlines Roche's continued commitment to the HIV market. Datamonitor's Laura Harris reports...

Published By Datamonitor

Richemont: well placed for luxury goods growth

Richemont is benefiting from strong demand in the luxury goods sector as consumers embrace top-end products from big name design houses, particularly for accessories. Richemont, with interests in luxury jewelry, watches, leather goods and writing instruments, is well positioned for growth.

Published By Datamonitor

Rewe: finally getting some Plus

Rewe has bought Tengelmann's 146 store-strong Plus discount operation in the Czech Republic. Present in the country since 1991, Rewe's future outlook seems bright, as the deal will strengthen its position in the region. That said, owing to turbulences in the financial markets, growth prospects in Eastern Europe have recently dimmed.

Published By Datamonitor

Ralph Lauren/Richemont: a profitable partnership

The Polo Ralph Lauren Watch and Jewelry Company SARL has been formed to design and create luxury watches and fine jewelry, to be sold through Ralph Lauren boutiques and independent jewelry and watch retailers worldwide from Autumn 2008. This venture should enhance the competitive position of both companies involved.

Published By Datamonitor

Productscan skincare review: from grocery bag to wash bag

Food ingredients such as grapes, wine and yogurt expanded into the health and beauty market this summer, as new product marketers used healthy foods and drinks for inspiration, reports Datamonitor's Productscan Online. Companies also found new ways to make products more portable than ever, a development which should please travelers and frequent fliers.

Published By Datamonitor

Plastic cards: Swiss to spend E17 billion via plastic in 2004

Published By Datamonitor